Products for Research Use Only
RegisterLogin

STM3006

CAT: 0804-HY-156773-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-156773-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM) . STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results[1][2].
CAS Number
2499664-52-5
UNSPSC
12352005
Target
Apoptosis; METTL3
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/stm3006.html
Purity
98.71
Solubility
DMSO : 116.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
BrC1=CC(C2=CN(CC3=CN4C=C(CN5CCC(C)(CC5)C)C=CC4=N3)N=N2)=C6C=NNC6=C1
Molecular Formula
C25H27BrN8
Molecular Weight
519.44
References & Citations
[1]Andrew A Guirguis, et al. Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.Cancer Discov. 2023 Oct 5;13 (10) :2228-2247.|[2]Brichkina A, et al. Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy. Signal Transduct Target Ther. 2023 Dec 11;8 (1) :448.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA2935-10STM3006

Popular Products